Ionis Reports 85-Week Results from the P-III Study (NEURO-TTRansform) of Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Shots:
- The company highlighted the 85wk. results from the P-III study evaluating the efficacy & safety of eplontersen in 168 patients with ATTRv-PN at 35, 66 & 85wk.
- The results showed that eplontersen continued to show a sustained reduction in serum TTR concentration over baseline at 85wk. & continued to halt disease progression as measured by the mNIS+7, improvement on Norfolk QoL-DN over baseline was observed with a favorable safety and tolerability profile
- The US FDA has accepted the NDA of eplontersen for ATTRv-PN with an anticipated PDUFA date of Dec 2023. The therapy also received ODD in the US & is currently being studied in the P-III study (CARDIO-TTRansform) for ATTR-CM
Ref: PR Newswire | Image: Ionis
Related News:- Ionis Reports Two-Year P-II OLE Study Results of Donidalorsen for the Treatment of Hereditary Angioedema
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
